echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Xinda biological class 1 innovative drug ibi322 approved clinical

    Xinda biological class 1 innovative drug ibi322 approved clinical

    • Last Update: 2020-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wen Jie winter On January 19, the data of CDE clinical tacit license column was updated, in which the class 1 innovative drug ibi322 of Cinda biology was approved for clinical application, and the indications were solid tumor and blood tumor Ibi-322 is an anti-CD47 / PD-L1 bispecific antibody, which inhibits the binding of CD47 to SIRP α and the binding of PD-L1 to PD-1 The preclinical study showed that ibi-322 can effectively induce the phagocytosis of tumor cells and stimulate the activation of T cells However, ibi-322 molecules are preferentially distributed in PD-L1 positive tumor cells, so as to reduce the potential side effects of this kind of target associated with single specific anti-CD47 antibody The preclinical data showed that ibi-322 had better in vivo efficacy, tumor accumulation and distribution, and higher safety than single specific anti-CD47 antibody According to Xinda's prospectus, the company currently has 5 bispecific antibody drugs under research, including: ibi-302, ibi-322, ibi-318, ibi-319, ibi-315 and ibi-323 According to insight database, three of the above-mentioned double antibodies have been used in phase 1 clinical practice in China, namely, ibi-315 and ibi-318 for advanced cancer and ibi-302 for wet age-related macular degeneration At present, 32 double antibody clinical trials have been carried out in China, 24 of which have been carried out by domestic enterprises, and kn026 and kn046 of kangningjierui, which have the fastest progress, have entered phase 2 clinical trials The figure below shows the clinical progress of double antibody in research of domestic enterprises, the picture source is insight database (https://db.dxy.cn/v5/clinical)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.